Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Robert S. Janssen"'
Autor:
Matthias Girndt, Manfred Plüer, Frank Dellanna, Ann K. Michelsen, Joachim Beige, Kai Toussaint, Hubert J. Wehweck, Michael Koch, Syrus Hafezi Rachti, Justus Faust, Hans-Peter Bosselmann, Oliver Witzke, Robert S. Janssen, the HBV-18 Study Investigators
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
This study compared the immunogenicity and safety of a booster dose of HepB-CpG (HEPLISAV-B® vaccine) with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in patients receiving chronic hemodialysis. This was a multicenter, randomized, open-label, p
Externí odkaz:
https://doaj.org/article/324437a38aa74c678935dcdd0ddf3fc9
Autor:
Robert S. Janssen, Abraham C.F. Leung, Robert L. Coffman, Albert F. Candia, Emmett V. Schmidt, Deborah J. Wong, Gregory A. Daniels, Minal Barve, Joseph J. Drabick, Anusha Kalbasi, Asim Amin, Shivaani Kummar, Theresa Medina, Antoni Ribas
Nanostring data from tumor biopsies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::200a8a48a97d8b2c46efc058b8084bba
https://doi.org/10.1158/2159-8290.22531799.v1
https://doi.org/10.1158/2159-8290.22531799.v1
Autor:
Robert S. Janssen, Abraham C.F. Leung, Robert L. Coffman, Albert F. Candia, Emmett V. Schmidt, Deborah J. Wong, Gregory A. Daniels, Minal Barve, Joseph J. Drabick, Anusha Kalbasi, Asim Amin, Shivaani Kummar, Theresa Medina, Antoni Ribas
Supplementary Table S1. Anti-PD-1/L1 treatment experience by SD-101 dose group. Supplementary Table S2. Overview of safety. Supplementary Table S3. Treatment-related events in 20% or more of patients in the total treatment cohort are presented. Suppl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4831adee7d9017fed180bb26a4325a33
https://doi.org/10.1158/2159-8290.22531796.v1
https://doi.org/10.1158/2159-8290.22531796.v1
Autor:
Matthias Girndt, Patricia Houser, Roberto Manllo-Karim, John E. Ervin, Chaim Charytan, Stephen Chow, Margarita Symonian-Silver, Lawrence Lehrner, Douglas Linfert, Douglas Shemin, Ann Michelsen, Fang Xie, Robert S. Janssen
Background: Hepatitis B virus (HBV) infection remains a significant global burden, especially for patients with chronic kidney disease (CKD) receiving hemodialysis. Three doses of HepB–CpG (HEPLISAV-B® vaccine) induced a superior immune response c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eff42cfbd6910f7af875bbc156f05e3
Autor:
Randall N. Hyer, Gregory A. Poland, Robert S. Janssen, Coline David, Katia Bruxvoort, Steven J. Jacobsen, Jeff Slezak
Publikováno v:
Vaccine. 39:5666-5672
Background In the absence of field efficacy studies, estimating the real-world effectiveness of vaccines may consider immunogenicity from randomized controlled clinical trials and real-world adherence. Combining seroprotection rates (SPRs) with regim
Autor:
Wei-Cheng Lian, Wang-Da Liu, Shan-Chwen Chang, Yi Jiun Lin, Erh-Fang Hsieh, Robert S. Janssen, Charles J.P. Chen, I-Chen Tai, Szu-Min Hsieh, Yu-Shan Huang
Publikováno v:
SSRN Electronic Journal.
Background: This was a phase 1, dose-escalation open-label trial to evaluate the safety and immunogenicity of MVC-COV1901, a SARS-CoV-2 S-2P protein vaccine adjuvanted with aluminum hydroxide and CpG 1018. Methods: 45 healthy adults from 20 to 49 yea
Autor:
Robert Lynn, Fang Xie, Adu Ntoso, German T Hernandez, Jeffrey J Connaire, Kimberly Erby, Robert S. Janssen, Lisa Rich, Kiranjit Dhillon, Heather Henderson, Ahmed M Awad, Randall N. Hyer
Publikováno v:
Vaccine. 39(25)
Background Hemodialysis patients are at increased risk of hepatitis B virus (HBV) infection and are poorly responsive to HBV vaccines. Current vaccine recommendations for hemodialysis patients utilize more than twice the amount of hepatitis B surface
Publikováno v:
Vaccine. 39(33)
The hepatitis B virus is highly infectious and can cause incurable liver disease, leading to high morbidity rates, increased healthcare utilization, and high mortality. Multiple preventative hepatitis B vaccine options have been available for decades
Publikováno v:
Vaccine. 36:2604-2611
Background Hepatitis B virus infection remains an important global public health problem. Approved alum-adjuvanted vaccines are well tolerated but require three doses and have reduced immunogenicity in adults. A two-dose vaccine containing hepatitis
Autor:
Sam Jackson, Joseph Lentino, James Kopp, Linda Murray, William Ellison, Margaret Rhee, Gerald Shockey, Lalith Akella, Kimberly Erby, William L. Heyward, Robert S. Janssen, Michael Adams, David Bolshoun, Tami Bruce, Rita Chuang, Donna DeSantis, Thomas Fiel, William Fitzgibbons, David Francyk, Harry Geisberg, Son Giep, Narendra Godbole, Terry Haas, Stephen Halpern, Anthony Inzerello, William Jennings, Scott Kaiser, Jennifer Kay, William Kirby, Robert Lending, Peter Levins, Clifford Molin, Michael Noss, Larry Kotek, Michele Reynolds, Ernie Riffer, Douglas Schumacher, Randall Severance, Royce Solano, Albert Tejada, Leslie Tharenos, Martin Throne, Merle Turner, Thomas Wolf, Mark Woodruff
Publikováno v:
Vaccine. 36:668-674
Background Hepatitis B virus infection remains an important public health problem in the United States. Currently approved alum-adjuvanted vaccines require three doses and have reduced immunogenicity in adults, particularly in those who have diabetes